Chiesi puts down $200M+ to collaborate with Affibody for respiratory diseases
The Italian drug developer Chiesi will be looking to drop nine figures to develop several treatments for respiratory diseases in a deal with Swedish biotech Affibody.
Chiesi and Affibody will work together on three programs using Affibody’s molecules against three targets. Chiesi will also fund the discovery and development work as well as commercialize the candidates worldwide, but Affibody will hold on to co-promoting the candidates in the Nordic region.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.